Serotet (Tetanus Human Immunoglobulin) for IM Injection

Serotet (Tetanus Human Immunoglobulin) – Passive Immunization for Tetanus Prophylaxis and Treatment

Serotet is a tetanus immune globulin (TIG) preparation administered by intramuscular injection to provide rapid, passive immunity against tetanus toxin. Formulated from purified human antibodies, Serotet offers immediate protection for individuals exposed to tetanus-contaminated wounds or those diagnosed with active tetanus infection.

Key Clinical Applications:

Tetanus prophylaxis in wound management—particularly for patients with incomplete or unknown tetanus toxoid vaccination history
Post-exposure immunization following contaminated injuries, surgical procedures, or burns
Adjunctive therapy in confirmed tetanus cases to neutralize circulating tetanus toxin
High-risk populations including immunocompromised patients and those with HIV/AIDS

Mechanism and Duration:

Serotet confers temporary passive immunity lasting approximately 3–4 weeks, providing critical protection during the window when active immunization (tetanus toxoid) takes effect. The preparation contains human-derived antibodies that bind and neutralize tetanus exotoxin, preventing neuromuscular complications.

Administration and Safety:

Administered exclusively by healthcare professionals in clinical settings via intramuscular injection. Dosing is individualized based on wound severity, exposure risk, and vaccination history. As a human blood-derived product, Serotet carries minimal transmission risk and should be considered before live virus vaccination; consultation with healthcare providers is recommended if vaccination is planned within 3 months of administration.

Serotet is essential for tetanus management in acute care and post-exposure scenarios where rapid passive immunization is clinically indicated.